M.D. Anderson Cancer Center
To learn if ivonescimab can help to control endocrine-refractory HR+ HER2- and/or TN mILC.
Primary Objectives To evaluate the 6-month PFS of ivonescimab in endocrine-refractory HR+ HER2- or Triple Negative (TN) mILC Secondary Objectives * To evaluate the 12-month PFS and median PFS (mPFS) of ivonescimab inhibitor in endocrine-refractory HR+ HER2- and TN mILC * To evaluate the overall response rate (ORR) of ivonescimab in endocrine-refractory HR+ HER2- and TN mILC * To assess the disease control rate (DCR), duration of response (DOR) and overall survival (OS) * To evaluate the safety and tolerability of ivonescimab, as assessed by the National Cancer Institute Common Terminology Cr…
Inclusion Criteria: * 18 years of age or older. * Historically confirmed invasive lobular cancer with negative E-cadherin staining by IHC. * Estrogen receptor (ER) positive (\>1%) or negative, progesterone receptor (PgR) positive or negative, and HER2-negative according to HER2 testing guidelines from the American Society of Clinical Oncology/College of American Pathologists. * Participants must be willing to undergo biopsy as required by the study if the tumor is safely accessible. * If ER+, participant must be endocrine refractory as per the treating oncologist assessment and has been expos…
Given by IV
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.